Latest from Joe
The most recent infographics and commentary, with the newest posts first.
The Next Wave of Obesity Medicine: 12 Investigational Therapies
Advancing Beyond Weight Loss: AHA Scientific Sessions 2026
Get to Know VK2735
Retatrutide vs Semaglutide 2 mg
Amylin: The Next Frontier in Obesity Medicine?
Retatrutide and Sleep Apnea: TRIUMPH-1-OSA and TRIUMPH-2-OSA
Obesity Medicine Is Advancing. Insurance Coverage Is Moving Backward.
CagriSema in Women: REDEFINE-1 Menopause Analyses
GLP-1s & Biological Aging: What the Evidence Actually Shows
GLP-1s and NAION: What the Evidence Actually Shows
EASD 2026 Obesity Medicine Roundup: A Comprehensive Review of the New Data
EASD 2026: 7 additional updates worth knowing
Big obesity announcements around EASD 2026
Why obesity medications deserve coverage
Four major obesity medicine pipeline updates
The combination-therapy era
Obesity & liver health
Lean mass is not muscle mass
Why weight loss differs in type 2 diabetes
GLP-1 cash-pay pricing: September 2026
Mounjaro gains a cardiovascular risk-reduction indication
The healthcare costs beyond the prescription
OASIS 5: the lower-dose question
